Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This study will enroll CML patients who have failed a first TKI stopping attempt. After
failure and at least a year of TKI treatment, patients will proceed to dasatinib treatment
for another 2 years. If MR4 or better is re-achieved and maintained for at least one year,
patients will be eligible for a second stop. After verification of MR4, TKI treatment will be
stopped and patients followed in the same manner as after first stop. If MMR is lost (BCR-ABL
>0.1% (IS)), TKI treatment will once again be restarted.
Phase:
Phase 2
Details
Lead Sponsor:
VU University Medical Center
Collaborators:
Aarhus University Hospital Helse Stavanger HF Helsinki University Central Hospital Henri Mondor University Hospital Odense University Hospital Skane University Hospital St. Olavs Hospital University Hospital, Bonn Uppsala University Hospital